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Increasing chronological age is the most significant
risk factor for human cancer development. To exam-
ine the effects of host aging on mammary tumor
growth, we used caveolin (Cav)-1 knockout mice as a
bona fide model of accelerated host aging. Mammary
tumor cells were orthotopically implanted into these
distinct microenvironments (Cav-1/ versus Cav-
1/ age-matched young female mice). Mammary tu-
mors grown in a Cav-1–deficient tumor microenvi-
ronment have an increased stromal content, with
vimentin-positive myofibroblasts (a marker associ-
ated with oxidative stress) that are also positive for
S6-kinase activation (a marker associated with aging).
Mammary tumors grown in a Cav-1–deficient tumor
microenvironment were more than fivefold larger
than tumors grown in a wild-type microenvironment.
278Thus, a Cav-1–deficient tumor microenvironment
provides a fertile soil for breast cancer tumor growth.
Interestingly, the mammary tumor-promoting effects
of a Cav-1–deficient microenvironment were estro-
gen and progesterone independent. In this context,
chemoprevention was achieved by using the mamma-
lian target of rapamycin (mTOR) inhibitor and anti-
aging drug, rapamycin. Systemic rapamycin treat-
ment of mammary tumors grown in a Cav-1–deficient
microenvironment significantly inhibited their tu-
mor growth, decreased their stromal content, and re-
duced the levels of both vimentin and phospho-S6 in
Cav-1–deficient cancer-associated fibroblasts. Since
stromal loss of Cav-1 is a marker of a lethal tumor
microenvironment in breast tumors, these high-risk
patients might benefit from treatment with mTOR in-
hibitors, such as rapamycin or other rapamycin-re-
lated compounds (rapalogues). (Am J Pathol 2012, 181:
278–293; http://dx.doi.org/10.1016/j.ajpath.2012.03.017)
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AJP July 2012, Vol. 181, No. 1Caveolin (Cav)-1 knockout (KO) mice represent an es-
tablished animal model of accelerated aging.1,2 Cav-1
KO mice have a significantly reduced life span,1 and
exhibit many signs of premature aging, such as in-
creased neurodegeneration, astrogliosis, reduced syn-
apses, and increased -amyloid production.2 Cav-1 KO
mice also exhibit other age-related pathological condi-
tions, such as benign prostatic hypertrophy,3 glucose
intolerance, insulin resistance, and other key features of
metabolic syndrome, but remain lean and are resistant to
diet-induced obesity.4–7 These phenotypic changes in
Cav-1 KO mice have been mechanistically attributed to
systemic metabolic defects.8 For example, Cav-1 KO
mice show evidence of increased oxidative stress and
mitochondrial dysfunction.8,9 In fact, knockdown of Cav-1
in fibroblasts, using a small-interfering RNA approach, is
sufficient to induce reactive oxygen species production
and DNA damage and to drastically reduce mitochon-
drial membrane potential.9–11 Thus, we and others have
concluded that Cav-1 KO mice are a new model for
mitochondrial oxidative stress and accelerated host ag-
ing.1,2,8,9,12 Because Cav-1 is a critical regulator of nitric
oxide production (via its interactions with nitric oxide syn-
thase) and cholesterol transport, increased nitric oxide
production and/or abnormal cholesterol transport have
been implicated in generating mitochondrial oxidative
stress in Cav-1–deficient fibroblasts.9–13
Recently, it has been proposed that oxidative stress
in the tumor microenvironment may lead to accelerated
host aging, with accompanying DNA damage, inflam-
mation, and a shift toward aerobic glycolysis (due to
the autophagic destruction of mitochondria).14,15 As a
consequence, oxidative stress and autophagy in the
tumor microenvironment produce high-energy nutri-
ents (eg, L-lactate and ketones) that can fuel tumor
growth via oxidative mitochondrial metabolism in can-
cer cells.8,16–22
Herein, we have used Cav-1 KO mice as a new
breast cancer stromal model to assess the potential
effects of oxidative stress and accelerated host aging
on mammary tumor growth in vivo. Tumors grown in
Cav-1–deficient mammary fat pads were significantly
larger (more than fivefold) and showed increased stro-
mal content, as predicted.
Oxidative stress is sufficient to drive myofibroblast
differentiation23,24 and is known to accelerate aging.25
In accordance with these findings, we show that Cav-
1–deficient cancer-associated fibroblasts (CAFs) have
increased levels of vimentin (a myofibroblast marker)
and phospho-S6 (a marker of increased aging). In fact,
deletion of S6-kinase is sufficient to dramatically in-
crease life span in mice, indicating that S6-kinase ac-
tivation is also a functional marker of accelerated
aging.26
Mammalian target of rapamycin (mTOR)/S6-kinase
signaling has been directly implicated in the process of
aging.27–30 In this context, rapamycin has been pro-
posed to function as an anti-aging drug by experimen-
tally extending life span in both normal mice and tumor-
bearing mice.27,31,32 Thus, we next examined whether
systemically shutting down mTOR/S6-kinase signalingwas sufficient to prevent the formation of mammary tu-
mors in a Cav-1–deficient microenvironment.
Remarkably, rapamycin treatment significantly inhib-
ited the growth of mammary tumors in a Cav-1–deficient
tumor microenvironment. Rapamycin effectively re-
duced the stromal content of these tumors; the levels of
vimentin and phospho-S6 were also significantly de-
creased in Cav-1–deficient CAFs. Thus, we should
consider using rapamycin (or its close relatives, the
rapalogues) for the chemoprevention of recurrence in
breast cancer patients who show an absence of stro-
mal Cav-1. In direct support of this notion of chemo-
prevention, rapamycin and its analogues have signifi-
cantly reduced the risk of developing multiple
malignancies in transplant patients.33,34
Importantly, a loss of stromal Cav-1 is a powerful pre-
dictive biomarker that is associated with early tumor re-
currence, lymph node metastasis, and tamoxifen resis-
tance, driving poor clinical outcome in breast cancer
patients.35–39 Similarly, a loss of stromal Cav-1 in patients
with ductal carcinoma in situ is predictive of recurrence and
progression to invasive breast cancer, up to 20 years in
advance.40 Similar results were also obtained with triple-
negative breast cancer patients.41 In TN patients, a loss of
stromal Cav-1 was associated with a 5-year survival rate of
10%. In the same patient cohort, TN patients with high
stromal Cav-1 had a survival rate of75% at up to 12 years
after diagnosis.41 Finally, in prostate cancer patients, a loss
of stromal Cav-1 is associated with advanced prostate can-
cer and metastatic disease, as well as a high Gleason
score, which is the current gold standard for predicting
prostate cancer prognosis.42 As such, Cav-1–deficient
mice are a validmodel for a lethal tumormicroenvironment.8
Consistent with these assertions, a loss of stromal
Cav-1 is a surrogate functional marker for aging, oxida-
tive stress, DNA damage, hypoxia, autophagy, and in-
flammation in the tumor microenvironment.10,11,13,21,43–46
In fact, genome-wide transcriptional profiling of laser-
captured tumor stroma isolated from Cav-1–negative
breast cancer patients showed the presence of multiple
gene signatures associated with aging, DNA damage,
inflammation, and even Alzheimer’s disease brain.46 Vir-
tually identical results were also obtained via the tran-
scriptional profiling of bone marrow–derived stromal cells
generated from young Cav-1 KO mice, further validating
a strict association with accelerated aging.8,13,16,47 Thus,
our current findings have important translational implica-
tions, specifically for the diagnosis and the therapeutic
stratification of breast cancer patients (ie, personalized
cancer medicine and/or theragnostics).
Materials and Methods
Animals
This study was conducted according to the guidelines
of the NIH and the Thomas Jefferson University Insti-
tute for Animal Studies. The approval was granted by
the Institutional Animal Care and Use Committee at
Thomas Jefferson University. Cav-1 KO mice were
280 Mercier et al
AJP July 2012, Vol. 181, No. 1Table 1. Transcriptional Overexpression of S6-Kinase and Ribosomal Proteins in Tumor Stroma Isolated from Breast Cancer Patients
Symbol Gene description Tumor stroma Recurrence stroma Metastasis stroma
Ribosomal protein S6 kinase
Rps6kl1 Ribosomal protein S6 kinase-like 1 2.59  1016 9.39  104
Rps6kb1 Ribosomal protein S6 kinase, polypeptide 1 6.12 1013 9.76  104
Rps6ka2 Ribosomal protein S6 kinase, polypeptide 2 8.69 1011 5.82  103
Rps6kb2 Ribosomal protein S6 kinase, polypeptide 2 1.10 1010 1.37  103
Rps6ka1 Ribosomal protein S6 kinase, polypeptide 1 1.43 1010 3.12  104
Rps6ka6 Ribosomal protein S6 kinase, polypeptide 6 2.60 109 4.52  102
Rps6ka5 Ribosomal protein S6 kinase, polypeptide 5 9.60 104
Rps6ka4 Ribosomal protein S6 kinase, polypeptide 4 1.55 102
Rps6ka3 Ribosomal protein S6 kinase, polypeptide 3 3.01  102
Ribosomal proteins
Rpl3l Ribosomal protein L3-like 1.37  1019
Rps9 Ribosomal protein S9 5.64  1015 2.27  103
Rpl22 Ribosomal protein L22 4.39  1012
Rpl23 Ribosomal protein L23 5.40  106
Rpl30 Ribosomal protein L30 7.77  104
Rps27l Ribosomal protein S27-like 3.89  102
Rpl21 Ribosomal protein L21 3.16  104
Rps7 Ribosomal protein S7 2.86  103
Rsl1d1 Ribosomal L1 domain-containing 1 1.74  102
Rps14 Ribosomal protein S14 2.45  102
Rpl7l1 Ribosomal protein L7-like 1 3.85  102
Rps24 Ribosomal protein S24 4.72  102
Mitochondrial ribosomal proteins
Mrp63 Mitochondrial ribosomal protein 63 1.27  1020
Mrps10 Mitochondrial ribosomal protein S10 9.11  1020
Mrpl20 Mitochondrial ribosomal protein L20 1.25  1017
Mrpl43 Mitochondrial ribosomal protein L43 1.71  1017 1.16  102
Mrps18b Mitochondrial ribosomal protein S18B 4.86  1017 1.83  103
Mrps6 Mitochondrial ribosomal protein S6 9.10  1014
Mrps12 Mitochondrial ribosomal protein S12 2.31  1011 2.55  102
Mrpl38 Mitochondrial ribosomal protein L38 2.36  109 4.20  102
Mrpl2 Mitochondrial ribosomal protein L2 2.13  107 1.98  102
Mrps25 Mitochondrial ribosomal protein S25 8.25  106 2.75  102
Mrps24 Mitochondrial ribosomal protein S24 3.06  105
Mrps34 Mitochondrial ribosomal protein S34 3.72  102 3.85  102
Mrpl9 Mitochondrial ribosomal protein L9 1.62  104 2.03  103
Mrpl55 Mitochondrial ribosomal protein L55 1.61  103 1.43  102
Mrpl49 Mitochondrial ribosomal protein L49 3.97  102
Mrpl52 Mitochondrial ribosomal protein L52 4.08  102
Mrpl3 Mitochondrial ribosomal protein L3 2.43  102
Mrpl33 Mitochondrial ribosomal protein L33 2.50  102
Mrpl4 Mitochondrial ribosomal protein L4 2.85  102
Mrps17 Mitochondrial ribosomal protein S17 3.87  102
Mrpl12 Mitochondrial ribosomal protein L12 3.95  102
Mrps5 Mitochondrial ribosomal protein S5 4.14  102
Upstream activators of S6 kinase
Pik3cd PI3K catalytic  polypeptide 3.43  1026 6.57  103
Pik3cg PI3K catalytic  polypeptide 5.82  1022 4.10  102
Pik3ap1 PI3K adaptor protein 1 7.87  1015 8.30  103
Pdpk1 PI3–dependent protein kinase-1 8.76  1014 8.65  104
Pik3c3 PI3K, class 3 3.74  1013
Pik3c2g PI3K, C2 domain,  1.31  105
Igf1 Insulin-like growth factor 1 9.71  1018
Rragc Ras-related GTP binding C 2.61  1018
Rraga Ras-related GTP binding A 2.92  1017
Akt3 V-akt thymoma viral oncogene homolog 3 2.18 1013
Rheb RAS-homolog enriched in brain 2.76  1012
Other mTOR downstream effectors/regulators
Prkaa2 Kinase, AMP-activated 2 catalytic 9.03  1025 1.50  104
Prkag3 Kinase, AMP-activated 3 noncatalytic 3.55  1012
Prkab2 Kinase, AMP-activated 2 noncatalytic 1.99  108
Prkaa1 Kinase, AMP-activated 1 catalytic 4.67  108 2.50  102
Prkag2 Kinase, AMP-activated 2 noncatalytic 5.02  108 1.10  102 2.19  102
Cdc42 Cell division cycle 42 homolog 2.46  1022 1.36  103
Eif4ebp2 Eif4e-binding protein 2 3.59  1017table continues
n bold a
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this study were in the FVB/N genetic background.
Materials
Mammary tumor (Met-1) cells were the generous gift of
Dr. Robert D. Cardiff (University of California–Davis).
Met-1 cells are a well-characterized TN mammary tumor
cell line (Robert D. Cardiff, personal communication).49
Rabbit polyclonal antibodies against vimentin (R28) and
phospho-S6 ribosomal protein (Ser235/236; 91B2) were
obtained from Cell Signaling Technology (Danvers, MA).
A mouse monoclonal antibody against minichromosal
maintenance 7 (141.2) and a rabbit polyclonal antibody
against Cav-1 (N-20) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). A mouse monoclonal
antibody to glyceradehyde-3-phosphate dehydrogenase
was obtained from Fitzgerald Industries International (Ac-
ton, MA) and was used as loading control. A rabbit poly-
clonal antibody against CD31 (28364) was obtained from
Abcam (Cambridge, MA). A mouse monoclonal antibody
against nucleophosmin/B23 (Fc-61991) was obtained
from Invitrogen (Carlsbad, CA). The immunohistochem-
istry (IHC) visualization kit LSAB2 was obtained from
Dako (Carpentaria, CA). Nuclear counterstains, such as
Hoechst 33342 and hematoxylin, were obtained from
Invitrogen and Sigma-Aldrich (St Louis, MO). Horse-
radish peroxidase–conjugated secondary antibodies
[anti-mouse (1:20,000 dilution) (Pierce Chemical,
Rockford, IL) or anti-rabbit (1:20,000 dilution) (BD Bio-
sciences, San Jose, CA)] were used to visualize bound
primary antibodies with the supersignal chemilumines-
cence substrate (Pierce Chemical). Fluorescein isothio-
cyanate– and tetrarhodamine isothiocyanate–conju-
gated secondary antibodies were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA). Pla-
cebo and rapamycin pellets (2.5 mg, 60 days, slow re-
lease) were obtained from Innovative Research of Amer-
ica (Sarasota, FL).
Orthotopic Injection of Met-1 Cells
Met-1 cells are a tumorigenic cell line established from a
mammary adenocarcinoma derived from a female
Table 1. Continued
Symbol Gene description
Eif4ebp1 Eif4e-binding protein 1
Eif4e Eukaryotic translation initiation factor 4E
Vegfb Vascular endothelial growth factor B
Ddit4l DNA damage–inducible transcript 4-like
Ulk2 Unc-51 like kinase 2 (Caenorhabditis elegans)
Ppp2r2b Protein phosphatase2 regulatory subunit B
Ppp2r1a Protein phosphatase2 regulatory subunit A
Ppp2r2c Protein phosphatase2 regulatory subunit B
Ppp2r2a Protein phosphatase2 regulatory subunit B
Hif1a Hypoxia-inducible factor 1,  subunit
P values for the overexpressed stromal gene transcripts are as shown
See the Materials and Methods for more details. Transcripts highlighted i
PI3K, phosphatidylinositol 3-kinase.MMTV-PyMT mouse, and are, thus, syngeneic to theFVB/N strain. Met-1 cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum, 2 mmol/L glutamine, 100 U/mL penicillin,
and 100 g/mL streptomycin. For the injections, 6- to
8-week-old female FVB/N wild-type (WT; Cav-1/) and
Cav-1 KO (Cav-1/) mice (n  11 to 13 per group) were
anesthetized with xylazine:ketamine (5 mg/kg:50 mg/kg),
and a ventral incision was performed to expose the
right fourth (inguinal) mammary gland. Met-1 cells (0.5
million in 50 L of complete growth media) were then
injected into the right mammary fat pad (inguinal 4)
using a 26-gauge needle. The incision was subse-
quently closed with a 5-0 silk suture. Tumor growth was
monitored during a 5-week period, and tumor size was
determined by weight. To calculate tumor incidence,
mice were divided into groups with tumors that
weighed 0.35 g (small), 0.35 to 0.8 g (medium), and
0.8 g (large).
Rapamycin Pellet Implantation
Implantation of slow-release pellets was performed un-
der anesthesia after the mammary fat pad injections.
The site of incision was shaved and scrubbed. The skin
was lifted on the lateral side of the neck of the animal,
and an incision equal in diameter to that of the pellet
was performed. Then, a horizontal pocket of approxi-
mately 2 cm beyond the incision site was generated to
introduce the pellet with forceps. The mice were ran-
domly assigned to groups receiving two placebo pel-
lets or two rapamycin pellets (2.5 mg, 60 days, slow
release).
Bilateral Ovariectomy Procedure
Mice underwent ovariectomy, as previously described.50
Briefly, 3- to 4-week-old female FVB/N WT and Cav-1 KO
mice were anesthetized using xylazine:ketamine (5 mg/
kg:50 mg/kg). A single dorsal incision, followed by liga-
tion of the ovarian arteries and veins with a 4-0 silk suture,
was performed, followed by the excision of both ovaries.
The incision site was subsequently closed with a 5-0 silk
Tumor stroma Recurrence stroma Metastasis stroma
1.41  105
1.16  1010 2.10  102
5.13  1012
4.76  1011
6.16 1011
1.24 108
4.06  103
2.76  103
3.94  102
2.10  106
ere extracted from Supplemental Tables S1–S3 found in Pavlides et al.47
re associated with recurrence and/or metastasis.
. Data wsuture.
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After the mice were sacrificed, inguinal mammary gland 4
was excised and fixed in formalin for 24 hours, paraffin
embedded, and cut into sections (5 m thick) for his-
tological analyses and IHC staining. For blood vessel
quantitation, five fields of CD31 staining per tumor
were taken with a 40 objective and the CD31-positive
vessels were counted and averaged. The tumors from
four to six mice were immunostained with CD31 anti-
body per group.
Western Blot Analysis
Western blot analysis was performed as previously de-
scribed.51 Briefly, mice were euthanized and the mam-
mary fat pad was dissected, weighed, and snap frozen in
liquid nitrogen. Samples were homogenized in radioim-
munoprecipitation (RIPA) assay [50 mmol/L Tris (pH 7.5),
150 mmol/L NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
Table 2. Transcriptional Overexpression of S6-Kinase and Ribos
Cancer Patients
Symbol Gene descrip
Ribosomal protein S6 kinase
Rps6ka3 Ribosomal protein S6 kinase, poly
Rps6ka3 Ribosomal protein S6 kinase, poly
Ribosomal proteins
Rps16 Ribosomal protein S16
Rps16 Ribosomal protein S16
Rps7 Ribosomal protein S7
Rps27 Ribosomal protein S27
Rps15A Ribosomal protein S15a
Rps9 Ribosomal protein S9
LOC100129381 Predicted: similar to ribosomal pr
Rps14 Ribosomal protein S14
Rpl7l1 Ribosomal protein L7-like 1
Mitochondrial ribosomal proteins
Lactb Mitochondrial 39S ribosomal prot
Lactb Mitochondrial 39S ribosomal prot
Mrpl9 Mitochondrial ribosomal protein L
Mrpl9 Mitochondrial ribosomal protein L
Mrpl49 Mitochondrial ribosomal protein L
Mrpl2 Mitochondrial ribosomal protein L
Mrps7 Mitochondrial ribosomal protein S
Upstream activators of S6 kinase
Akt3 V-AKT thymoma viral oncogene h
Pdpk1 PI3–dependent protein kinase-1
Mtor Mammalian target of rapamycin (
Pik3cg PI3K catalytic  polypeptide
Pik3ap1 PI3K adaptor protein 1
Pik3c2a PI3K class 2  polypeptide
Rhebl1 Ras homolog enriched in brain lik
Other mTOR downstream effectors/regulators
Ppp2r5c Protein phosphatase2, regulatory
Prkag2 Kinase AMP-activated  2 noncat
Cdc42 Cell division cycle 42 (GTP-bindin
Hif1a Hypoxia-inducible factor 1  subu
Eif4ebp2 Eukaryotic translation initiation fac
P values and fold changes in stromal gene transcript expression are
al.46 See the Materials and Methods for more details. Transcripts highlight
entry is shown for a gene transcript; these represent the results obtained
used are available in Supplemental Table S2 in Witkiewicz et al.46 n  4
As a consequence, gene transcripts with a P  0.1 were included, because of
PI3K, phosphatidylinositol 3-kinase.and 0.1% SDS]52 lysis buffer with complete miniprotease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN)
and phosphatase inhibitor cocktails from Sigma-Aldrich.
After homogenization, samples were sonicated and cen-
trifuged at 12,000  g for 10 minutes. Samples were
separated by SDS-PAGE (12% acrylamide) and trans-
ferred to a nitrocellulose membrane for probing. Subse-
quent wash buffers consisted of 10 mmol/L Tris (pH
8.0), 150 mmol/L NaCl, and 0.05% Tween 20. Mem-
branes were blocked in 10 mmol/L Tris (pH 8.0), 150
mmol/L NaCl, and 0.05% Tween 20 supplemented with
5% bovine serum albumin (Sigma-Aldrich) or 5% nonfat
dry milk (Carnation, Solon, OH) for 1 hour at room tem-
perature. The membranes were subsequently incubated
with a given primary antibody for 3 hours at room tem-
perature. Primary antibodies were used at a range of 1 to
2.5 g/mL dilution. Horseradish peroxidase–conjugated
secondary antibodies were used to visualize bound pri-
mary antibodies with the supersignal chemiluminescence
substrate (Pierce Chemical).
roteins in Cav-1–Deficient Tumor Stroma Isolated from Breast
P value
Fold change
(Cav-1/Cav-1)
e 3 0.01 1.90
e 3 0.04 1.89
0.02 3.86
0.05 3.19
0.06 2.62
0.01 2.57
0.02 2.40
0.1 1.92
7 0.04 1.69
0.04 1.66
0.08 1.35
; -lactamase 0.002 4.62
; -lactamase 0.04 1.80
0.003 2.11
0.005 1.87
0.04 1.84
0.06 1.70
0.05 1.48
3 0.03 2.62
0.007 2.15
threonine kinase) 0.06 2.02
0.1 1.93
0.045 1.79
0.05 1.50
0.1 1.50
it B=,  0.02 3.00
0.02 2.23
ein 25 kd) 0.03 1.81
0.1 1.39
binding 0.1 1.33
Data were extracted from Supplemental Table S2 found in Witkiewicz et
ld overlap with the genes listed in Table 1. In some cases, more than one
re than one probe set for a given gene transcript. The specific probe sets
with high stromal Cav-1, and n  7 patients with absent stromal Cav-1.omal P
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peptid
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otein S
ein L56
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IHC was performed as previously described.50 Briefly,
paraffin-embedded sections (5 m thick) of fat pads
(containing tumor cells) were dehydrated in xylene for 10
minutes and rehydrated in a series of graded ethanols
and distilled water for 5 minutes. The slides were then
incubated in a citric acid–based antigen unmasking so-
lution with an acidic pH (Vector Labs, Burlingame, CA)
using an electric pressure cooker on high pressure for 5
to 10 minutes. The slides (six to eight per group) were
incubated in 3% hydrogen peroxide (Thermo Fisher
Scientific, Hampton, NH) for 30 minutes at room tem-
perature and blocked with 10% goat normal serum
(Jackson ImmunoResearch Laboratories) for 1 hour at
room temperature and incubated with a given primary
antibody overnight at 4°C. The following day, slides
were washed with PBS once and incubated with a
biotinylated mouse or rabbit secondary antibody in-
cluded in the IHC visualization kit (LSAB2). The remain-
der of the protocol was performed according to the
manufacturer’s instructions. The slides were counter-
stained using Mayer’s hematoxylin. The slides were
dehydrated with graded alcohols and left in xylene for
15 minutes before mounting with Permount (Thermo
Fisher Scientific). The images were acquired at 40
and 60 magnification.
Immunofluorescence
For immunofluorescence, the same protocol as IHC
was used, with the exception of the peroxidase block-
ing step, and the secondary antibodies used were
fluorescein isothiocyanate and tetrarhodamine isothio-
cyanate conjugated (1:300). The slides were counter-
stained with Hoechst 33342 (1:1000) and mounted with
Prolong Gold antifade solution (Invitrogen). The tumors
were imaged with a confocal microscope (Zeiss LSM
510; Carl Zeiss, Thornwood, NY). Images were acquired
with 63 and 100 objectives.
Statistical Analysis
All of the statistical analysis was performed using a one-
way analysis of variance, followed by a Tukey-Kramer
multiple comparison test, unless otherwise stated. P 
0.05 was considered significant.
Mining of Transcriptional Profiling Data
The transcriptional profiles of laser-captured tumor
stroma,46,53 isolated from human breast cancer patients,
were re-examined for evidence of elevated mTOR/S6-
kinase signaling, essentially as we previously described
for other signaling pathways related to glycolysis, lyso-
somal degradation, and autophagy.8,47 More specifically,
the data presented in Table 1 were from published DNA
microarray data from Pavlides et al47 using fresh-frozen
invasive breast cancer samples with their matching be-
nign control subjected to laser microdissection to specif-
ically isolate the stromal compartment. The data pre-sented in Table 2 were obtained from published DNA
microarray data from Witkiewicz et al46 using fresh-frozen
breast cancer samples subjected to laser capture micro-
dissection to specifically isolate the stromal RNA from
Cav-1–positive (n 4) and Cav-1–negative (n 7) breast
cancer stromal compartments.
Results
Cav-1–Negative Mammary Stroma Accelerates
Met-1 Tumor Growth in Vivo
Recent reports have shown an association between re-
duced stromal Cav-1 and unfavorable outcome in breast
cancer patients.41 To understand the mechanisms un-
A
B
C
Figure 1. Cav-1–negative mammary stroma increases mammary tumor growth
in vivo. A: Representative images of mammary glands after orthotopic injections
of Met-1 cells show accelerated tumor growth in Cav-1 KO mice. Images were
acquired using an Olympus DP71 camera (Center Valley, PA) with DP manager
software (MacKinney Systems, Springfield, MO) version 3.1.1.208, using a 1.5
objective. B: Quantitative analysis of tumor weight shows an approximately
fivefold increase. *P 0.001 (n 11 to 13 per group). Mice were injected in the
right mammary fat pad, resulting in only one tumor per mouse. C: Approxi-
mately 90% of the Cav-1 KO mice developed medium-large tumors compared
with only 40% in the WT group.derlying this phenomenon, we injected Met-1 into WT and
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1A, the tumors grown in Cav-1 KO mammary fat pads
were significantly larger and more vascularized than
those grown in their WT counterparts. Quantitatively, as
shown in Figure 1B, Met-1 tumors grown in the fat pads of
Cav-1 KO mice were approximately fivefold larger than
those grown in WT fat pads (n  11 and n  13, respec-
tively; P  0.01). When tumor size was further examined,
approximately 90% of the Cav-1 KO mice developed
medium-to-large tumors compared with only approxi-
mately 40% in the WT group (Figure 1C).
Mammary Tumors Grown in Cav-1 KO Mice
Display Increased Angiogenesis and More
Stromal Content
For a tumor to grow beyond approximately 2 mm in
diameter, the generation of new blood vessels is nec-
essary, a process known as angiogenesis.54 As such,
we postulated that increased angiogenesis could con-
tribute to the accelerated tumor growth observed in
Cav-1 KO fat pads. In fact, tumors grown in Cav-1 KO
mammary fat pads are more vascularized, as reflected
by an increased abundance of CD31-positive vessels
(Figure 2).
In addition to being larger and more vascularized,
Cav-1 KO tumors were also significantly more stromal-
ized (a high stroma/epithelia ratio). This is depicted in
Figure 3 by increased Masson’s trichrome staining
(blue). An increase in collagen secretion is suggestive
of the presence of fibroblasts (Figure 3).55 In fact,
increased vimentin staining, a marker of myofibro-
blasts, was also observed in tumors grown in Cav-1 KO
fat pads (Figure 3).Tumor Stroma of Cav-1 KO Mice Is
Hyperproliferative
The increased collagen deposition and vimentin-positive
staining in Cav-1 KO fat pads suggested the presence of
stromal proliferative fibroblasts. As predicted, dual label-
ing with a proliferation marker (MCM7) and vimentin an-
tibody revealed that Cav-1 KO stromal cells were more
proliferative (Figure 4).
Cav-1 KO CAFs Show Hypertrophied Nucleoli
and Elevated Levels of Nucleophosmin/B23
Cav-1–negative CAFs found in mammary tumors were
more proliferative; thus, we predicted that they would
have an increased need for protein synthesis. Our IHC
results revealed that CAFs in Cav-1–negative tumors
showed enhanced B23/nucleophosmin expression, a nu-
cleolar protein involved in ribosomal biosynthesis56–58
(Figure 5, A and B).
Cav-1 KO Tumor Stroma Displays an Activated
mTOR Pathway
To date, few studies have examined the contribution of
stromal protein synthesis machinery in tumor growth and
progression. In fact, Cav-1 KO mammary tumors showed
increased phosphorylation of the ribosomal protein S6 at
serine 235/236 (pS6), a downstream effector of mTOR
activity.59 As depicted in Figure 6, we observed an in-
verse relationship between Cav-1 and pS6 expression in
stromal fibroblasts. Fibroblasts found both inside and
outside the Cav-1 KO tumors had more pS6 compared
with those in WT tumors (Figure 6, A and B). In contrast,
epithelial pS6 remained unaffected by the presence of
Figure 2. Cav-1–negative mammary stroma in-
creases tumor vascularization. Representative im-
ages of CD31 staining of tumors resulting from
Met-1 orthotopic injections show increased vessel
formation in tumors grown in Cav-1 KOmammary
fat pads. Staining shows results from IHC of CD31
(brown) with nuclear counterstain (blue) and con-
focal microscopy of CD31 (red) immunostaining
and Hoechst (blue). Original magnification, 40
(CD31) and 63 (CD31/Hoechst).Cav-1 (Figure 6).
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Growth of Cav-1 KO Mammary Tumors
Hyperactivation of the protein synthesis machinery and
increases in mTOR pathway signaling in Cav-1 KO
CAFs might contribute to the accelerated growth of
mammary tumors. To test this hypothesis, mice in-
jected with Met-1 cells were treated with rapamycin
(RAPA), a specific mTOR inhibitor. Remarkably, daily
rapamycin treatment (2.78 g/kg per day) for 5 weeks
prevented mammary tumor growth in Cav-1 KO mice,
as reflected by tumor weight (Figure 7A; n  11 and
n  12, respectively; P  0.001). To ensure the dose of
rapamycin used was sufficient to inhibit mTOR activity,
we assessed the levels of pS6, its downstream effector.
As depicted in Figure 7B, although the levels of pS6
were significantly elevated in tumors grown in Cav-1
KO mice, rapamycin treatment prevented mTOR activ-
ity. This observation was also independently validated
by IHC (Figure 8). Rapamycin treatment prevented tu-
mor growth in Cav-1 KO mice and also decreased
collagen deposition, vimentin staining, and angiogen-
esis (Figure 9, A–C).CD31-Positive Vessels Are Decreased in the
Tumors of Cav-1 KO Mice Treated with
Rapamycin
As depicted in Figure 9, the tumors grown in Cav-1 KO
mice had increased CD31 staining, suggesting an in-
crease in angiogenesis. To quantitatively assess the
levels of angiogenesis, the number of blood vessels
was counted by assessing CD31-positive vessels in
each tumor before and after rapamycin treatment. Al-
though tumors grown in Cav-1 KO fat pads had 30
blood vessels per field, the number of vessels de-
creased almost twofold after rapamycin treatment,
reaching the levels observed in the tumors grown in WT
mice (Figure 10).
Mammary Tumor Growth in Cav-1 KO Mice Is
Hormone Independent
To exclude the possibility that mammary tumors grew
faster in Cav-1 KO fat pads because of differential hor-
monal sensitivity of the host’s mammary fat pad, we per-
formed a bilateral ovariectomy (OVX). Figure 11 shows
Figure 3. Increased amounts of stroma in tu-
mors grown in Cav-1 KO fat pads. A complex
collagen network was detected in H&E-stained
tumors by an intense pink staining. Masson’s
trichrome stain also reveals the presence of col-
lagen, as depicted by a blue stain. To detect the
presence of fibroblasts embedded within the
collagen network, tumors were immunostained
with a vimentin antibody. Cav-1 KO tumors have
more vimentin-positive cells. Arrows, stromal
cells. Original magnification, 60.that tumor formation was not affected by depletion of
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success of the ovariectomy procedure was confirmed
by measuring uterine atrophy, as previously de-
scribed.50 Interestingly, tumors still grew approxi-
mately 4.5-fold bigger in ovariectomized Cav-1 KO
mice when compared with their WT counterparts (P 
0.01; n  9 and n  12, respectively). Most important,
even in the absence of ovarian hormones, rapamycin
successfully prevented tumor growth in Cav-1 KO mice
(4.2-fold; P  0.01 compared with Cav-1 KO/OVX-
placebo). Also important, there was no significant dif-
ference between Cav-1 KO/Sham-RAPA versus Cav-1
KO/OVX-RAPA (P  0.486).
Transcriptional Evidence that mTOR/S6-Kinase
Signaling in the Tumor Microenvironment
Is Increased in Human Breast Cancer
Patients
To further assess the clinical relevance of our current
findings, we next re-examined the transcriptional profiles
of human tumor stroma that was isolated from a series of
breast cancer patients, via laser-capture microdissec-
tion.53 These data included three complementary gene
sets that were also associated with clinical outcome.47
i) The Tumor Stroma versus Normal Stroma List evaluated
the transcriptional profiles of tumor stroma obtained from
53 patients with normal stroma obtained from 38 patients
(containing 6777 genes).47 ii) The Recurrence Stroma
List evaluated the transcriptional profiles of tumor stroma
obtained from 11 patients (with tumor recurrence) with
the tumor stroma of 42 patients (without tumor recur-
rence) (containing 3354 genes).47 iii) The Lymph-Node(LN) Metastasis Stroma List evaluated the transcriptional
profiles of tumor stroma (obtained from 25 patients with
LN metastasis) with the tumor stroma of 25 patients (with-
out LN metastasis) (containing 1182 genes).47 All gene
transcripts that were up-regulated in the tumor stroma of
patients were all selected and assigned a P value, with a
cutoff of P  0.05.
The results of this analysis are summarized in Table 1.
Many gene transcripts associated with mTOR/S6-kinase
signaling, and S6-kinase itself, and other ribosomal pro-
teins were all specifically up-regulated in the tumor stroma
of human breast cancer patients. Interestingly, many mito-
chondrial ribosomal proteins were also up-regulated. Such
a large increase in the anabolic protein synthesis machinery
may be a necessary stress response to compensate for the
onset of catabolic protein degradation, via autophagy and
mitophagy, in the tumor stroma. Many of these overex-
pressed transcripts were also specifically associated with
tumor recurrence and LN metastasis.
To further assess the association of mTOR/S6-kinase
signaling with a Cav-1–deficient tumor stroma, we next
re-examined the gene profiles obtained from human tu-
mor stroma isolated from breast cancer patients that
were separated based on the status of stromal Cav-1.46
The results of this analysis are summarized in Table 2.
Importantly, many of the same mTOR/S6-kinase–related
gene transcripts were specifically elevated in patients with a
loss of stromal Cav-1 (highlighted in bold), as predicted. In
this regard, Lactb (a mitochondrial ribosomal protein) is one
of the gene transcripts that was most highly up-regulated in
the stroma of patients with a loss of Cav-1. In light of these
clinical data, our current results using Cav-1–deficient mice
as a preclinical model may have important translational
Figure 4. Increased vimentin and stromal
MCM7 in tumors grown in Cav-1 KO fat pads.
Confocal microscopy demonstrating dual label-
ing of vimentin and MCM7 is shown. These re-
sults demonstrate that tumors grown in a Cav-1
KO fat pad have increased levels of proliferating
fibroblasts, as shown by increased expression of
nuclear MCM7 staining in vimentin-positive
cells. Representative fields were taken using a
63 oil objective. Hoechst 33342 was used as a
nuclear counterstain (blue), along with vimentin
(green) and MCM7 (red). Arrows, stromal cells.significance for human breast cancer patients.
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New evidence suggests a dynamic function of the sur-
rounding tumor stroma in breast cancer pathogene-
sis.60–63 Cav-1, an important tumor suppressor, was re-
cently shown to be expressed in the tumor-associated
stroma.35,36 Importantly, a loss of stromal Cav-1 is a
powerful predictive biomarker that is associated with
early tumor recurrence, LN metastasis, and tamoxifen
resistance, driving poor clinical outcome in breast cancer
patients.35–39 Although these clinical data suggest that
Cav-1 can serve as a predictive biomarker of disease
outcome, more studies were warranted to understand the
mechanisms involved.
To gain a better understanding of the prognostic value
of a loss of stromal Cav-1, mammary tumor cells isolated
from the MMTV-PyMT tumor model (Met-1) were injected
into the mammary fat pads of WT and Cav-1 KO mice.
Interestingly, a lack of Cav-1 expression in the mam-
mary fat pad greatly accelerated tumor formation. The
present results are in accordance with previous tumor
transplantation experiments in Cav-1 KO fat pads,
which also suggested a growth-inhibiting property of
stromal Cav-1.64 Furthermore, recent xenografts and
co-injection experiments showed that knockdown of
Cav-1 expression in human immortalized fibroblasts
was sufficient to accelerate the growth of MDA-MB-231
A
B
Figure 5. Increased levels and colocalization of nucleophosmin/B23 and
phospho-S6 in tumors grown in Cav-1 KO mice. A: Cav-1 KO mice have
increased levels of stromal nucleophosmin/B23, as depicted by brown stain-
ing. B: The stromal cells in Cav-1 KO tumors that are positive for nucleo-
phosmin/B23 staining (red) are also positive for pS6 staining (green). A
merged image is shown (right panel). All images were acquired using a
100 oil objective.breast cancer cells.12A striking morphological feature of the mammary tu-
mors grown in Cav-1 KO fat pads was the increased
amount of collagen deposition and the presence of spin-
dle-shaped fibroblasts embedded within the tumor mass
(Figure 3). In contrast, tumors grown in WT mammary fat
pads were almost entirely epithelial. Previous studies de-
scribed the prognostic value of an abundant stroma
(stroma rich) versus an epithelial-dominant tumor mass
(stroma poor). For example, colon and breast tumors with
abundant stroma showed an increased risk of relapse
and a poor prognosis.65,66 More specifically, TN breast
tumors with less stroma have a 5-year relapse-free rate of
81% compared with 56% for those with abundant stroma.
Mechanistically, the prominence of collagen deposition
and an increased number of fibroblasts found in the
Cav-1 KO tumor stroma could be explained by increased
stromal proliferation. In fact, Cav-1 KO CAFs showed
increased nuclear expression of the proliferative marker
MCM7 (Figure 4). These results suggest that a lack of
stromal Cav-1 in tumor could promote the proliferation of
fibroblasts.
A
B
Figure 6. Tumors grown in Cav-1 KO mice have increased expression
of stromal phospho-S6. Tumors grown in Cav-1 KO mice display in-
creased pS6 staining (brown) in the fibroblasts embedded within the
tumors (A) and in the fibroblasts surrounding the tumors (B). In contrast,
WT fibroblasts express significantly less pS6 staining. Original magnifica-
tion, 40.
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predict cellular transformation for years, and abnormal-
ities in nucleolar shape have been reported in cancer
as early as the 19th century.67 The nucleolus is an
important cellular component involved in ribosome pro-
duction. Most often, increased cellular proliferation re-
sults in an increased demand for cellular constituents,
leading to increased protein synthesis, ribosome pro-
duction, and nucleolar hypertrophy.68 In fact, we no-
ticed that Cav-1 KO CAFs have more prominent nucle-
oli and hypothesized that they required increased
protein synthesis to sustain their greater proliferative
rates. Accordingly, Cav-1 KO CAFs expressed signifi-
cantly more B23/nucleophosmin, a nucleolar protein
necessary for ribosomal RNA transcription and pro-
cessing (Figure 5).
mTOR, the mammalian target of rapamycin, is a serine/
threonine kinase that is often overexpressed or activated
in cancer cells and that regulates protein synthesis, cell
growth, and survival. Few studies have examined the role
of the mTOR pathway in CAFs and tumor growth.69 Con-
sistent with B23/nucleophosmin overexpression, a re-
A
B
Figure 7. Tumors grown in Cav-1 KO fat pads are rapamycin sensitive. A:
Tumor growth in Cav-1 KO mice was reduced by as much as 4.7-fold after
rapamycin treatment when compared with placebo-treated mice (P 
0.001). For rapamycin treatment, 11 WT and 12 Cav-1 KO mice received
rapamycin treatment, whereas 13 WT and 11 Cav-1 KO mice received
placebo only. B:Western blot analysis showing the hyperactivation of pS6
and its complete inhibition by rapamycin treatment. Total S6, GAPDH,
and Cav-1 are shown as control (CTL) of equal loading and to demon-
strate the lack of Cav-1 in the tumor stroma of Cav-1 KO mice. *P  0.001
vs WT-placebo; †P  0.001 vs WT-rapamycin; ‡P  0.001 vs Cav-1 KO-
placebo.markable increase in mTOR activity was observed inCav-1 KO CAFs, as reflected by increased pS6 protein
levels (Figures 6 and 7). Consistent with an activated
mTOR pathway in the stroma of Cav-1–depleted mam-
mary tumors, these tumors were highly responsive to
mTOR inhibitors, such as rapamycin, as seen by the
prevention of tumor growth (Figure 7). To our knowledge,
although this is the first report of mTOR activation in
Cav-1 KO CAFs. A recent study reported that keloids,
a dermal fibroproliferative disorder of scar fibroblasts,
also display hyperactivation of the mTOR pathway.70 In
fact, the proliferation of keloids can be inhibited by
rapamycin.70 The hyperactivation of mTOR in Cav-1
KO CAFs is not surprising because they share several
similarities with keloids, such as increased prolifera-
tion, aberrant growth factor secretion, and increased
extracellular matrix production and contractile pro-
teins.71,72 Interestingly, recent reports have shown that
stromal phosphatase and tensin homolog (PTEN), an
upstream inhibitor of phosphatidylinositol 3-kinase,
can inhibit mammary tumor development in an ErB2
breast cancer mouse model.73
Morphologically, rapamycin-treated Cav-1 KO tumors
showed less collagen, had decreased tumor-associated
fibroblasts, and had significantly less angiogenesis, as
reflected by decreased CD31 staining; all of these char-
acteristics predict a good clinical outcome in pa-
tients65,66,74–77 (Figure 9). Previous reports have sug-
gested that human breast CAFs can directly promote
angiogenesis through the expression of stromal cell–de-
Figure 8. Status of stromal phospho-S6 immunostaining in mammary tu-
mors after rapamycin treatment in WT and Cav-1 KO mice. After a 5-week
treatment with rapamycin, the tumor size reverts to that of WT tumors.
Mammary tumor sections were immunostained with a phospho-specific an-
tibody directed against phospho-S6. Tumors grown in Cav-1 KO mice display
increased pS6 staining (brown) in the tumor-associated fibroblasts (arrows);
this staining was ablated by rapamycin treatment (Cav-1 KO  RAP) and
appears as tumors grown in a WT microenvironment.
rome (B
Cav-1 and Aging in Cancer 289
AJP July 2012, Vol. 181, No. 1rived factors.78,79 Furthermore, we previously reported
that a lack of Cav-1 expression in mammary fat pads is
linked to increased angiogenesis. Indeed, mammary
fibroblasts derived from Cav-1 KO mice revealed in-
creased levels of angiogenesis-related gene tran-
scripts.50,72 The decrease in angiogenesis observed after
rapamycin treatment in tumors grown in Cav-1 KO mice
(Figure 10) is interesting andmight suggest the involvement
of the stromal mTOR pathway on blood vessel formation in
these Cav-1–deficient stromal tumors.
A
B
C
Figure 9. Morphological characteristics of mammary tumors after rapamy
rapamycin, the tumor size reverts to that of WT tumors. Rapamycin significa
number of fibroblasts in the tumor stroma (C), as depicted by CD31 (A), trich
objective.
Figure 10. Blood vessel quantitation in the tumors grown in WT and Cav-1
KO mice before and after rapamycin (RAPA) treatment, showing the number
of blood vessels per field. A total of five fields were photographed at 40
magnification per group and averaged. *P  0.001 between Cav-1 KO (KO)
†and WT; P  0.001 between Cav-1 KO  placebo (PLAC) and Cav-1 KO 
RAPA.Previous reports have suggested that the anti-tumor
effects of rapamycin are estrogen dependent, thus ne-
glecting its potential therapeutic efficacy in estrogen-
independent and tamoxifen-resistant breast cancer pa-
tients.80 To test whether rapamycin would retain its
therapeutic potential in breast cancer patients with low
stromal Cav-1 in the absence of ovarian hormones, we
subjected the mice to bilateral ovariectomies. Interest-
ingly, the accelerated tumor growth observed in Cav-1
PA) treatment in WT and Cav-1 KO mice. After a 5-week treatment with
reases the levels of angiogenesis (A), collagen deposition (B), and the total
), and vimentin (C) immunostains, respectively. Original magnification, 60
Figure 11. Accelerated mammary tumor growth in Cav-1 KO mice is
hormone independent. Tumor weight after tumor cell injection and rapa-
mycin treatment in OVX WT and Cav-1 KO mice is depicted. Cav-1 KO
mice develop larger tumors and remain rapamycin sensitive in the ab-
sence of ovarian hormones. *P  0.001 versus WT sham; †P  0.001
‡cin (RA
ntly decversus WT-OVX-PLACEBO; P  0.01 versus Cav-1 KO-OVX-PLACEBO;
§P  0.05 versus Cav-1 KO sham.
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dure (Figure 11). These results suggest a hormone-inde-
pendent role for stromal Cav-1 in breast tumor growth.
More important, rapamycin also dramatically prevented
tumor growth in ovariectomized Cav-1 KO mice. The
present results suggest the potential clinical value of
mTOR inhibitors in premenopausal and postmenopausal
TN breast cancer patients with decreased stromal Cav-1,
as well as in estrogen receptor–positive tamoxifen-resis-
tant breast cancer patients.
Recent mechanistic studies have proposed that Cav-1
might constitute an important link between cancer cells
and the tumor stroma.8 Metabolomics and gene profiling
studies of the Cav-1 KO mammary gland have revealed
signatures associated with oxidative stress, mitochon-
drial dysfunction, and aerobic glycolysis.8 This new
model proposes that a loss of Cav-1 expression is suffi-
cient to induce oxidative stress in stromal fibroblasts.
These events result in lysosome-driven degradation of
organelles (autophagy or mitophagy) in CAFs, which re-
lease energy-rich nutrients. These recycled stromal nu-
trients can then be used by the adjacent epithelial cancer
cells, resulting in net energy transfer to cancer cells and
accelerated tumor growth.8,10,11,81
The phosphatidylinositol 3-kinase/mTOR/S6-kinase
pathway has previously been linked to oxidative
stress.82–85 S6-kinase is the upstream activator of pS6
and was recently required for starvation-induced au-
tophagy.86,87 High levels of autophagy can actually be
detrimental to cells,87 and mTOR activation protects
cells against high levels of autophagy.87–89 Thus, the
increased mTOR/S6-kinase signaling observed in Cav-1
KO CAFs might be a compensatory response to protect
fibroblasts from abnormally high levels of autophagy. Inter-
estingly, Narita et al90 have recently come to a similar con-
clusion.91 They directly showed that anabolic protein syn-
thesis, via mTOR signaling, is an important stress response
in cells undergoing catabolic protein degradation via en-
hanced autophagy,90 and may lead to an enhanced se-
cretory phenotype, with the increased production of IL-6
and IL-8.90 However, they did not examine the role of
Cav-1 in this process or relate this metabolic phenotype
to tumorigenesis.
The role of the mTOR pathway in oxidative stress–
induced proliferation was also previously reported. Hy-
drogen peroxide can induce the proliferation of lung
cells that, in turn, can be inhibited by rapamycin.82
Some reports also suggest that retinoblastoma (RB) is
a downstream target of mTOR in adipocytes and pros-
tate and ovarian cancer cells.92–94 Interestingly, we
previously reported dysregulation of the RB pathway
by Cav-1 in human breast CAFs.71 Thus, the increased
proliferative potential of Cav-1–negative CAFs sur-
rounding breast tumors might contribute toward a
worse prognosis due to mTOR-dependent oxidative
stress–induced proliferation, suggesting a new axis in
the stroma of breast tumors (Cav-1¡mTOR¡RB) (Fig-
ure 12). Whether breast cancer patients with low stro-
mal Cav-1 expression have more CAFs, increased stro-
mal mTOR, and an inactivated RB pathway remains to
be examined.Apart from its role in autophagy and cancer, mTOR
hyperactivation was recently linked to aging.28 For in-
stance, rapamycin treatment can increase the life span
of cancer-prone mice.95 Interestingly, a loss of Cav-1
in mice results in accelerated aging and a decreased
life span.1,2 Whether rapamycin treatment could in-
crease the longevity of Cav-1 KO mice remains to be
determined. The current results suggest that a Cav-1–
negative tumor stroma possesses all of the character-
istics of an aging organ and might contribute to poor
disease outcome and shorten the life span of patients
because of hyperactivated stromal mTOR signaling.
In conclusion, the present study investigated the
downstream mechanisms involved in the growth-pro-
moting effects of a Cav-1–negative tumor stroma in
mammary tumors. We show that Cav-1–negative
stroma provides a fertile soil for breast tumor growth.
These tumors display a proliferative stroma with hyper-
activated mTOR signaling. The treatment of these mice
with rapamycin prevented tumor growth, an effect in-
dependent of estrogen and progesterone. Thus, our
results suggest that the levels of Cav-1 in the microen-
vironment (Cav-1 rich versus Cav-1 poor) can directly
promote the growth of breast tumors, which can be
prevented by mTOR inhibitors, such as rapamycin.
Breast cancer patients with low stromal Cav-1 levels
have a poor prognosis. Whether mTOR inhibitors could
prevent tumor growth and increase survival rates in
breast cancer patients with decreased stromal Cav-1
remain to be investigated and could have a major
clinical impact. In conclusion, we describe a new net-
work between stromal Cav-1 and mTOR signaling,
which can be used to design more effective treatments
Figure 12. Mechanistic diagram summarizing the function of stromal Cav-1
in the mTOR pathway and tumor growth. The levels of Cav-1 expression in
the CAFs dictate how tumor cells grow in the mammary fat pad. Fibroblasts
lacking Cav-1 expression display significantly more mTOR activation, caus-
ing the surrounding tumor cells, through paracrine actions, to grow and
develop into significantly larger tumors. This accelerated growth induced by
a Cav-1–negative stroma can be specifically prevented by the pharmacolog-
ical inhibition of the mTOR pathway with rapamycin.for breast cancer patients.
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